Global X China Biotech Innovation ETF CHB
6.64 USD 0.00 (+0.00%)
At closeFeb 16, 2024, 4:00 PM EST
6.64 Day range 6.70
6.63 52-week range 9.76
- Market cap
- 1.39M
- EPS (ttm)
- 0.492514
- P/E ratio
- 13.48
- Volume
- 154
- Avg volume
- 712
- Open
- 6.70
- Previous close
- 6.64
- Day's range
- 6.64 – 6.70
- 52-week range
- 6.63 – 9.76
No chart data for this range yet.
Key statistics
- Enterprise value
- 0
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 7.26
- 200-day average
- 7.66
About Global X China Biotech Innovation ETF
The fund invests at least 80% of its total assets, plus borrowings for investments purposes (if any), in the securities of the underlying index and in American Depositary Receipts ("ADRs") and Global Depositary Receipts ("GDRs") based on the securities in the underlying index. The underlying index is designed to provide exposure to exchange-listed companies that are directly involved in China’s biotechnology industry. It is non-diversified.
News
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) 
Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB) 
Hibsago (bepirovirsen) Approved in the US for the Treatment of Chronic Hepatitis B (CHB) 
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B 
Challenger Assays Extend New Open Pittable Mineralisation 
Gyre Therapeutics Announces NMPA Acceptance of New Drug Application for F351 (hydronidone) for CHB-Induced Liver Fibrosis Treatment 
Challenger West Assays Return Grades up to 60g/t Au 
First Challenger Assays Return Grades up to 170g/t Au 
Gyre Therapeutics Announces China's NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis Treatment 
Gyre Therapeutics' Hydronidone Met the Primary Endpoint and Demonstrated Statistically Significant Fibrosis Regression in Pivotal Phase 3 Trial for the Treatment of CHB-associated Liver Fibrosis in China
Your note
Sign in to keep a note on CHB — it syncs with the Stock Master app.